Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Swedish Orphan Biovitrum announces approval for Cometriq in Europe


Tuesday, 25 Mar 2014 07:00am EDT 

Swedish Orphan Biovitrum publ AB:Says the European Commission has approved Cometriq (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).Says the European Commission granted conditional marketing authorisation following a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) issued in Dec. 2013. 

Company Quote

85.7
-0.15 -0.17%
6:36am EDT